Arch Biopartners Inc. ARCH.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | 114.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | 114.30K |
| Cost of Revenue | 157.70K | 117.70K | 360.20K | -100.30K | 82.90K |
| Gross Profit | -157.70K | -117.70K | -360.20K | 100.30K | 31.30K |
| SG&A Expenses | 150.30K | 179.90K | 687.50K | 228.00K | 174.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 308.00K | 297.60K | 1.05M | 127.70K | 257.30K |
| Operating Income | -308.00K | -297.60K | -1.05M | -127.70K | -143.00K |
| Income Before Tax | -343.30K | -379.80K | -1.12M | -195.90K | -175.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -343.30K | -379.80K | -1.12M | -195.90K | -175.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -343.30K | -379.80K | -1.12M | -195.90K | -175.20K |
| EBIT | -308.00K | -297.60K | -1.05M | -127.70K | -143.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | -0.01 | -0.02 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 67.93M | 66.94M | 66.11M | 65.51M | 66.11M |
| Average Diluted Shares Outstanding | 67.93M | 66.94M | 66.11M | 65.51M | 66.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |